NCT00688714

Study to Investigate Safety and Tolerability of a Single Dose of AZD6482

A Randomised, Double-Blind, Placebo-Controlled Phase I Study to Assess the Tolerability, Safety, Pharmacokinetic, and Pharmacodynamic Properties of AZD6482, Alone and co-Administered With ASA, After Single Ascending Intravenous Doses to Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

AZD6482 is a new drug substance aiming to prevent blood clots which may arise in atherosclerotic blood vessels and cause myocardial infarction or stroke. This is the first study with AZD6482 in humans. The primary aim for this study is to evaluate the safety and tolerability of AZD6482 in healthy human volunteers. How the substance is metabolised and eliminated from the body will also be studied. This will be done by comparing the effect of single ascending doses of AZD6482 to placebo (inactive substance).

Conditions

• Antiplatelet Effect

Interventions

Type	Name	Description
DRUG	AZD6482	0,9-364,5 mg administrated through intravenous infusion over 3 hours
DRUG	Placebo

Timeline

• Start date: 2008-01-01
• Primary completion: 2008-05-01
• Completion: 2008-05-01
• First posted: 2008-06-03
• Last updated: 2008-06-03